Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Ionis Pharma (IONS) aims to complete Phase 1/2 study of ISIS-HTTRx (ISIS 443139) in Patients with Early Manifest Huntington's Disease in 2017

Source Link:: https://clinicaltrials.gov/ct2/show/NCT02519036?term=Ionis+Pharmaceutical&recr=Open&no_unk=Y&rank=8

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

IONS

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details First therapy designed to directly target the cause of disease as opposed to treating the symptoms

http://ir.isispharm....

Additional Relevant Details Update on Dec 11 2017: In the Phase 1/2a study, dose-dependent reductions of mHTT were observed in participants treated with IONIS-HTTRx. In addition, the safety and tolerability profile of IONIS-HTTRx observed in the Phase 1/2a study supports continued development. Ionis and Roche plan to present results from this study at medical conferences in the first half of 2018 and plan to submit the study results for publication in a peer-reviewed medical journal. Ionis and Roche have also recently initiated an open-label extension (OLE) study for patients who completed the Phase 1/2a study.

http://ir.ionispharm...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Dec 11, 2017

Occurred Source:

http://ir.ionispharma.com/news-releases/news-release-details/ionis-pharmaceuticals-licenses-ionis-htt-rx-partner-following

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2 Study, Isis-httrx, Isis 43139, Huntington's Disease